Mural Oncology PLC (NASDAQ:MURA – Get Free Report) was the target of a significant increase in short interest during the month of August. As of August 31st, there was short interest totaling 608,200 shares, an increase of 193.4% from the August 15th total of 207,300 shares. Based on an average daily volume of 263,300 shares, the short-interest ratio is currently 2.3 days. Approximately 4.8% of the shares of the company are short sold. Approximately 4.8% of the shares of the company are short sold. Based on an average daily volume of 263,300 shares, the short-interest ratio is currently 2.3 days.
Mural Oncology Stock Up 0.5%
Mural Oncology stock opened at $2.08 on Monday. Mural Oncology has a 52 week low of $0.95 and a 52 week high of $4.74. The business has a 50-day simple moving average of $2.14 and a 200 day simple moving average of $2.41. The stock has a market cap of $36.03 million, a price-to-earnings ratio of -0.24 and a beta of 3.00.
Get Mural Oncology alerts:
Mural Oncology (NASDAQ:MURA – Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported ($1.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.13) by ($0.64). On average, research analysts anticipate that Mural Oncology will post -7.54 earnings per share for the current year.
Institutional Trading of Mural Oncology
Several large investors have recently modified their holdings of MURA. Jane Street Group LLC bought a new stake in Mural Oncology during the 4th quarter valued at approximately $68,000. Concurrent Investment Advisors LLC bought a new stake in Mural Oncology during the 1st quarter valued at approximately $28,000. Two Sigma Advisers LP bought a new stake in Mural Oncology during the 4th quarter valued at approximately $84,000. Quadrature Capital Ltd bought a new stake in Mural Oncology during the 2nd quarter valued at approximately $98,000. Finally, Northern Trust Corp boosted its position in Mural Oncology by 22.0% during the 4th quarter. Northern Trust Corp now owns 39,966 shares of the company’s stock valued at $129,000 after acquiring an additional 7,197 shares in the last quarter. 80.21% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Separately, Wall Street Zen downgraded Mural Oncology from a “hold” rating to a “strong sell” rating in a research report on Sunday, August 10th. Two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Mural Oncology has a consensus rating of “Moderate Buy” and a consensus price target of $12.00.
Check Out Our Latest Research Report on Mural Oncology
Mural Oncology Company Profile
(Get Free Report)
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company’s lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Read More
Five stocks we like better than Mural Oncology
Technology Stocks Explained: Here’s What to Know About Tech
Best Bang For Your Buck? 2 Bargain Stocks with 30%+ Upside
Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
Football Season Is Here and DraftKings Stock Is Surging
How to Start Investing in Real Estate
RH Stock Slides After Mixed Earnings and Tariff Concerns